Subscribe
Sven Hansche / Shutterstock.com
3 September 2025NewsEuropeSarah Speight

UK firm expands in Germany with more litigation hires

Carpmaels & Ransford appoints two litigation partners as the UK firm expands its presence in Germany in response to UPC demand.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
UPC issues first decision on second medical use
13 May 2025   Court of First Instance rules on Sanofi v Amgen antibodies dispute | Claims dismissed as “unfounded” and lacking in evidence | All parties ordered to pay costs totalling €45m ($50m).


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Europe
UPC issues first decision on second medical use
13 May 2025   Court of First Instance rules on Sanofi v Amgen antibodies dispute | Claims dismissed as “unfounded” and lacking in evidence | All parties ordered to pay costs totalling €45m ($50m).

More on this story

Europe
UPC issues first decision on second medical use
13 May 2025   Court of First Instance rules on Sanofi v Amgen antibodies dispute | Claims dismissed as “unfounded” and lacking in evidence | All parties ordered to pay costs totalling €45m ($50m).

More features

Sandoz blocked by UK court from seeking Xarelto profits
The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
‘This is not a rescue deal’: How an acquisition fits London firm's plan
Alston & Bird partner with strong Japanese ties jumps to new firm
Chinese invisible braces maker hits back at infringement claims